AFMD Affimed N.V. Stock Quote

AFMD [NASD]

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	2.79%	Shs Outstand	114.79M	Perf Week	-2.36%
Market Cap	995.32M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	0.00%	Shs Float	109.37M	Perf Month	13.48%
Income	-47.20M	PEG	-	EPS next Q	-0.11	Inst Own	57.10%	Short Float	6.93%	Perf Quarter	35.28%
Sales	27.00M	P/S	36.86	EPS this Y	-56.50%	Inst Trans	23.30%	Short Ratio	2.21	Perf Half Y	170.94%
Book/sh	0.65	P/B	14.63	EPS next Y	28.30%	ROA	-37.70%	Target Price	14.65	Perf Year	340.28%
Cash/sh	1.11	P/C	8.54	EPS next 5Y	-	ROE	-100.40%	52W Range	1.88 - 10.79	Perf YTD	63.40%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-77.20%	52W High	-14.04%	Beta	2.65
Dividend %	-	Quick Ratio	2.20	Sales past 5Y	44.60%	Gross Margin	-	52W Low	393.35%	ATR	0.80
Employees	128	Current Ratio	2.20	Sales Q/Q	400.00%	Oper. Margin	-	RSI (14)	59.77	Volatility	9.00% 7.41%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	60.20%	Profit Margin	-	Rel Volume	0.82	Prev Close	9.51
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Apr 15 BMO	Payout	-	Avg Volume	3.43M	Price	9.27
Recom	1.70	SMA20	9.56%	SMA50	30.54%	SMA200	78.70%	Volume	655,156	Change	-2.47%

Mar-31-21

Initiated

Credit Suisse

Outperform

$15

Mar-28-19

Initiated

SVB Leerink

Outperform

Aug-28-18

Upgrade

Jefferies

Hold → Buy

Jul-14-17

Initiated

SunTrust

Buy

Aug-12-16

Downgrade

Leerink Partners

Outperform → Mkt Perform

May-19-16

Downgrade

Leerink Partners

Outperform → Mkt Perform

Dec-10-15

Initiated

Laidlaw

Buy

$15

Dec-04-15

Initiated

Wells Fargo

Outperform

Sep-09-15

Initiated

Jefferies

Hold

Aug-06-15

Reiterated

Oppenheimer

Outperform

$14 → $19

Jun-22-15

Reiterated

Jefferies

Buy

$12 → $16

Apr-15-21 05:18PM	Why Affimed N.V. Stock Dropped Today Motley Fool -8.23%
12:29PM	Natural Killer Cells and Other Promising Cancer Treatments Barrons.com
06:30AM	Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress GlobeNewswire
06:30AM	Affimed NV to Host Earnings Call ACCESSWIRE
Apr-12-21 09:37AM	Company News for Apr 12, 2021 Zacks
06:30AM	Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I GlobeNewswire
Apr-09-21 02:44PM	Here's Why Shares of Affimed Skyrocketed Today Motley Fool +23.45%
07:04AM	Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal Toxicity Benzinga
05:59AM	Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 GlobeNewswire
Apr-08-21 06:30AM	Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021 GlobeNewswire
Mar-31-21 10:14AM	Affimed To Study AFM24/SNK-01 Combo In Solid Tumor Settings Benzinga +7.77%
06:30AM	Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors GlobeNewswire
Mar-20-21 03:24AM	What Type Of Shareholders Own The Most Number of Affimed N.V. (NASDAQ:AFMD) Shares? Simply Wall St.
Mar-10-21 05:22PM	Affimed Announces Presentations at the AACR Annual Meeting 2021 GlobeNewswire +23.77%
01:50PM	Why Affimed N.V. Stock Is Soaring Today Motley Fool
08:26AM	Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim Data Benzinga
06:30AM	Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility Analysis GlobeNewswire
Feb-03-21 08:42AM	Affimed Partners With Roche To Develop AFM24 Combo Therapy In EGFR Expressing Solid Tumors Benzinga
07:31AM	The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga
06:30AM	Affimed Announces Collaboration with Roche to Study AFM24 in Combination with PD-L1 Checkpoint Inhibitor in EGFR Expressing Solid Tumors GlobeNewswire
Jan-15-21 09:21AM	Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-14-21 08:36AM	Affimed (AFMD) Catches Eye: Stock Jumps 8.8% Zacks
Jan-13-21 06:15AM	Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares GlobeNewswire +8.76%
Jan-12-21 04:01PM	Affimed Announces Proposed Public Offering of Common Shares GlobeNewswire +5.41%
Jan-11-21 06:45AM	Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
06:30AM	Affimed Announces 25 Million Debt Financing Agreement with Silicon Valley Bank GlobeNewswire
Jan-07-21 06:30AM	Affimed Announces Pipeline and Business Update GlobeNewswire +8.78%
Dec-20-20 01:02AM	Is Affimed (NASDAQ:AFMD) Using Debt Sensibly? Simply Wall St.
Dec-15-20 08:40PM	Is AFMD A Good Stock To Buy Now? Insider Monkey
Dec-08-20 08:03AM	The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga
Dec-07-20 10:01AM	Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma GlobeNewswire +20.46%
Nov-20-20 07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-19-20 04:01PM	Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSDs anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood GlobeNewswire +8.07%
Nov-10-20 02:30PM	Affimed N.V. (AFMD) Q3 2020 Earnings Call Transcript Motley Fool +13.14%
08:40AM	The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga
07:55AM	Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:35AM	Affimed: Q3 Earnings Insights Benzinga
06:30AM	Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress GlobeNewswire
Nov-09-20 04:01PM	Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets GlobeNewswire +9.06%
10:17AM	Affimed Earnings Preview Benzinga
08:20AM	New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimeds AFM13 and Cytokine-Activated Natural Killer Cells GlobeNewswire
Nov-05-20 04:01PM	Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies GlobeNewswire
Nov-04-20 04:05PM	Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition GlobeNewswire +11.01%
06:30AM	Affimed to Present at Upcoming Investor Conferences GlobeNewswire
Nov-03-20 06:30AM	Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020 GlobeNewswire
Oct-29-20 06:32AM	How Should Investors Feel About Affimed's (NASDAQ:AFMD) CEO Remuneration? Simply Wall St.
Oct-26-20 11:55PM	4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29) Insider Monkey
Oct-20-20 06:30AM	Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy GlobeNewswire
Oct-14-20 05:15PM	Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire -6.15%
Oct-06-20 06:30AM	Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13 GlobeNewswire
06:30AM	AbCheck s.r.o. Receives Grant to Further Develop a Discovery Technology for Functional Antibodies using Microfluidics GlobeNewswire
Sep-29-20 06:30AM	Affimed to Present at Jefferies Virtual Cell Therapy Summit GlobeNewswire
Sep-14-20 06:21AM	Are Institutions Heavily Invested In Affimed N.V.'s (NASDAQ:AFMD) Shares? Simply Wall St.
Sep-02-20 06:30AM	Affimed to Present at Upcoming Investor Conferences GlobeNewswire
Aug-17-20 03:30PM	Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks TipRanks
Aug-11-20 07:31PM	Affimed N.V. (AFMD) Q2 2020 Earnings Call Transcript Motley Fool -9.87%
07:55AM	Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:29AM	Affimed: Q2 Earnings Insights Benzinga
06:30AM	Affimed Reports Second Quarter 2020 Financial Results and Operational Progress GlobeNewswire
Aug-10-20 10:57AM	Earnings Outlook For Affimed Benzinga
Aug-05-20 06:30AM	Affimed Announces Two New Appointments to Its Supervisory Board GlobeNewswire
Aug-04-20 06:30AM	Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020 GlobeNewswire
Jul-31-20 08:23AM	Introducing Affimed (NASDAQ:AFMD), A Stock That Climbed 76% In The Last Three Years Simply Wall St.
Jul-29-20 12:33PM	Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -5.03%
Jul-10-20 06:30AM	Affimed Announces Annual General Meeting of Shareholders GlobeNewswire
Jun-30-20 11:03AM	Will Affimed Continue to Surge Higher? Zacks
Jun-29-20 08:43AM	Implied Volatility Surging for Affimed (AFMD) Stock Options Zacks
Jun-28-20 05:57PM	Hedge Funds Have Never Been This Bullish On Affimed NV (AFMD) Insider Monkey
Jun-25-20 06:02AM	Affimed N.V. (NASDAQ:AFMD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates Simply Wall St. +13.20%
Jun-23-20 07:57AM	The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout Benzinga
07:04AM	Affimed: Q1 Earnings Insights Benzinga
06:30AM	Affimed Reports First Quarter 2020 Financial Results and Operational Progress GlobeNewswire
06:30AM	Affimed NV to Host Earnings Call ACCESSWIRE
Jun-22-20 09:20AM	Affimed Announces Presentation of Data on Genentechs RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimeds ROCK® Platform, at AACR Virtual Annual Meeting II GlobeNewswire +13.66%
Jun-18-20 08:34AM	The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga
Jun-17-20 06:30AM	Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers GlobeNewswire
Jun-16-20 09:47AM	Affimed (AFMD) Catches Eye: Stock Jumps 7.2% Zacks +8.23%
06:30AM	Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-12-20 02:23AM	Edited Transcript of AFMD earnings conference call or presentation 28-Apr-20 12:30pm GMT Thomson Reuters StreetEvents
Jun-11-20 06:30AM	Affimed Announces Appointment of Angus Smith as Chief Financial Officer GlobeNewswire -7.41%
May-29-20 08:05AM	Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting GlobeNewswire +5.45%
May-28-20 05:00AM	Affimed to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-15-20 05:00AM	Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II GlobeNewswire +19.19%
May-03-20 08:12AM	Downgrade: Here's How Analysts See Affimed N.V. (NASDAQ:AFMD) Performing In The Near Term Simply Wall St.
May-01-20 08:07AM	Earnings Update: Affimed N.V. (NASDAQ:AFMD) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St. -7.31%
Apr-29-20 12:00PM	All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy Zacks
Apr-28-20 06:31PM	Affimed N.V. (AFMD) Q4 2019 Earnings Call Transcript Motley Fool
08:30AM	Affimed: Q4 Earnings Insights Benzinga
06:35AM	Affimed Reports 2019 Financial Results and Recent Operational Progress GlobeNewswire
Apr-16-20 07:30AM	Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers GlobeNewswire
Apr-02-20 07:57AM	The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation Benzinga
06:30AM	Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 GlobeNewswire
Apr-01-20 04:01PM	Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma GlobeNewswire
Mar-26-20 07:30AM	Affimed Announces Participation at Upcoming Virtual Investor Conferences GlobeNewswire
Mar-24-20 04:00PM	Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies ACCESSWIRE
Mar-17-20 07:30AM	Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer GlobeNewswire +15.97%
Feb-19-20 07:30AM	Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire
Feb-03-20 07:30AM	Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer GlobeNewswire
Jan-10-20 06:30AM	Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer GlobeNewswire
Jan-07-20 03:23PM	Edited Transcript of AFMD earnings conference call or presentation 19-Nov-19 1:30pm GMT Thomson Reuters StreetEvents

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience